Premium
Rosuvastatin therapy for dyslipidemia and other associated parameters in Saudi metabolic syndrome patients
Author(s) -
Rafeeq Misbahuddin,
Habib Hamed,
Murad Hussam,
Gari Mamdouh,
Gazzaz Zohair
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.lb630
Subject(s) - rosuvastatin , dyslipidemia , medicine , metabolic syndrome , national cholesterol education program , wilcoxon signed rank test , lipid profile , statistical significance , diabetes mellitus , gastroenterology , endocrinology , cholesterol , mann–whitney u test
Background Metabolic syndrome (MS) is a constellation of metabolic irregularities comprising dyslipidemia, hypertension, hyperglycemia, chronic inflammatory, and hypercoagulable state predisposing to diabetes and cardiovascular events. Statins are first‐line drugs to treat the associated atherogenic dyslipidemia. Aim Effect of rosuvastatin on dyslipidemia and other abnormalities of MS in Saudi patients was studied. Settings and Design Prospective, open label, randomized clinical study. Materials and Methods Patients of either sex ≥18 years (n = 153) having MS as per modified National Cholesterol Education Program Adult Treatment Panel III criteria were prescribed rosuvastatin 10 mg OD for 24 weeks. Serum lipids, biochemical, clinical, and anthropometric parameters were studied before and after treatment. Statistical Analysis Used Statistical Package for Social Sciences version17 was used. Descriptive analysis was used for all variables and documented as mean ± SD. Normality checked by Shapiro–Wilk test, Kurtosis and Skewness Z‐score, and visualization of histograms. Lipid levels and other parameters before and after treatment were evaluated by paired t‐test for parametric data and Wilcoxon signed rank test for nonparametric data. Pretreatment and posttreatment values were correlated by Pearson's correlation coefficient. Multiple regression analysis was performed to see effect of other variables. Results 142 patients completed the study. Highly significant reduction was observed in LDL‐C, TC, TG, VLDL‐C, non‐HDL‐C, Lipoprotein(a) and atherosclerotic index with an elevation in HDL‐C. A total of 86% patients reached LDL‐C goal of ≤ 100 mg/dL. Beneficial response was observed on other associated parameters. There was strong correlation between pre‐treatment and post‐treatment values. No significant effect of age, gender, BMI, obesity and baseline cholesterol was observed on mean cholesterol reduction. No serious/severe adverse effects were reported. Conclusion Rosuvastatin markedly improved atherogenic dyslipidemia of MS besides beneficial effects on other abnormalities. Support or Funding Information This paper contains the results and findings of a research project that is funded by king Abdulaziz city for science and technology (KACST) (Grant no. ARP‐34‐129)